Teva files potential blockbuster migraine drug for FDA approval
Israel's Teva to move US HQ from Pennsylvania to New Jersey | The Times of Israel
Teva warns on 2018 profit, may face migraine drug delays | ロイター
Pfizer Wins $2.15B Patent Suit with Teva, Sun Pharma | Fox Business
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
EU fines drug makers for keeping cheap medicine off market
Migraine treatment results in Japan boost Teva - Globes
Allergan sells generic drug unit to Israel's Teva for $40.5 billion - Los Angeles Times
Teva seeks blockbuster drug to succeed Copaxone - Globes
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva to cut 14,000 jobs | Business | Chemistry World
EU antitrust authorities launch probe of Teva over Copaxone drug | The Times of Israel
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
With appeals court win, Takeda scores blockbuster Velcade patent reprieve till 2022 | Fierce Pharma
Teva Pharmaceuticals to lay off 14,000 employees worldwide, 1,750 in Israel - The Jerusalem Post
Teva Pharmaceutical Stock Could Double | Barron's
Sex, drugs, and sharing trade secrets
Teva Pharmaceuticals considers laying-off 10,000 workers - The Jerusalem Post
Teva Pharmaceutical: Slow Road To A Higher Share Price (NYSE:TEVA) | Seeking Alpha
New branded drugs helping Teva Pharm move closer to growth | Reuters
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
Teva Is Easy Pill to Swallow - WSJ
